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Thrombolytic agents may be useful in the treatment of cerebral ischemia caused by arterial
thrombosis or embolic occlusion. A trial of intravenous human tissue-type plasminogen activator
(rt-PA) was carried out in seven male Sprague-Dawley rats subjected to embolic cerebral
ischemia, with eight control animals. One-hour-old autogenous blood clot was injected into the
internal carotid artery. A 30-minute infusion of 10 g,g/kg/minute of rt-PA or saline followed.
Areas of ischemia at two hours post-embolization were assessed by digital image processing of
serial iodo-'4C-antipyrine autoradiographic images. The volumes of "no-flow" (NF) and "low-
flow" (LF) regions were calculated.
One animal in each group suffered no detectable ischemia; the remainder had well-defined
regions of middle and posterior cerebral artery ischemia. No animal sustained a hemorrhagic
lesion. Treatment produced no noticeable effect on the patency ofcervical vessels. Total NF and
LF volumes were less for the treated group but did not reach statistical significance by t-test. In
middle cerebral distribution sections, however, LF volume was significantly less (p < 0.05) for
treated animals (150 vs. 191 mm3), primarily due to a more significant decrease in LF volume in
the anterior-middle cerebral overlap zone (47 vs. 90 mm3;p < 0.025). Fibrinogen levels were not
altered by drug treatment (p > 0.30).
INTRODUCTION
Cerebrovascular ischemic events frequently involve a combination of embolic and
thrombotie processes. Vascular thrombosis may occur as a result of abnormalities in
the vessel intima (including the presence of a natural or foreign thrombogenic
substance) or in the characteristics ofthe circulating blood. Treatment ofa thrombotic
cerebrovascular occlusion with a thrombolytic agent is a complex situation because of
the risk ofhemorrhage in an area of the brain in which there is dysautoregulation and
ischemic damage to vascular structures. In theory, a thrombolytic agent might prevent
expansion of an infarcted area by halting propagation of a thrombus or preventing
occlusion ofsmall collateral vessels.
Tissue plasminogen activator (t-PA), a peptide produced by vascular endothelium
[1], converts plasminogen to plasmin, a key step in the fibrinolytic pathway. Tissue PA
of human origin has recently become available in quantity by means of recombinant
DNA technology [2]. Unlike other activators ofplasminogen such as streptokinase and
urokinase, human PA is effective when given intravenously, has not been shown to
produce systemic anticoagulation with fibrinogen degradation, and carries a reduced
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risk of causing peripheral embolization [3,4,5]. In addition, PA is ten times more
effective than urokinase in bringing about clot dissolution [6].
The effect ofexogenously administered plasminogen activator in the setting ofacute
stroke due to cerebrovascular thrombosis is unknown. We have developed a model of
ischemia involving embolization with homologous blood clot [7], a variant of that
described by Kudo et al. [8] and Kaneko et al. [9]. Reproducible regions of
hypoperfusion defined by iodo-['4C]-antipyrine autoradiography are produced in the
middle and posterior cerebral artery territories secondary to occlusion of proximal
vessels at the base of the brain. The purpose of this investigation is to assess the effect
of intravenous PA infusion on the volume of ischemic tissue in this model of embolic
cerebral ischemia in the rat.
METHODS
Experimental Procedure
A total of fifteen male Sprague-Dawley rats weighing from 314 to 459 grams were
used. The animals were anesthetized lightly with ether and injected intraperitoneally
with 40 milligrams per kilogram of sodium pentobarbital (Nembutal, 50 mg/cc,
Abbott Laboratories). A tracheostomy was performed, followed by insertion of right
femoral arterial and venous polyethylene catheters. Arterial pressure was continually
recorded via transducer and chart recorder (Grass Instrument Co.). Temperature was
monitored by rectal probe and maintained at approximately 370C. Anesthesia was
maintained with intermittent intravenous and intraperitoneal doses of pentobarbital.
Arterial blood gases were measured by capillary tube sampling prior to embolization
andjust prior to sacrifice.
In accordance with the previously described procedure [7], theright pterygopalatine
artery was dissected free, ligated with 4-0 silk suture, and coagulated distal to the
ligature. The external carotid artery was ligated distally and cannulated with
polyethylene catheter (PE-50, Clay Adams; inner diameter 0.58 mm, outer diameter
0.965 mm). With a temporary clip occluding the common carotid artery at the base of
the neck, 0.1 cc of homologous clot (derived from approximately 0.7 cc of blood) was
injected by hand into the external carotid catheter against resistance over two minutes.
The common carotid clip was removed and the catheter withdrawn from the external
carotid artery, which was then coagulated.
An intravenous infusion ofhuman tissue-type plasminogen activator (t-PA; Genen-
tech, Inc., South San Francisco, CA) was begun at a rate of 10 ,gg/kg/minute as the
common carotid clip was removed. The drug was diluted in saline to provide a total
volume of 1.0 cc. Seven animals received PA for 30 minutes post-embolization
(approximately 12,000 IU). Eight animals received 1.0 cc ofsaline for the same period
oftime.
Prior to sacrifice at 120 minutes post-embolization, 0.9 cc of blood was withdrawn
for fibrinogen determination. A dose of 0.24 milliCuries (mCi)/kg of 4-[N-Methyl-
'4C]-iodoantipyrine in saline (0.1 mCi/cc, American Radiolabeled Chemicals Inc., St.
Louis, MO) was injected intravenously, followed ten seconds later by 2 cc ofsaturated
potassium chloride solution.
Preparation ofTissue
Handling oftissue specimens proceeded as previously described [7]. Frozen sections
ofbrain, 32 microns thick, were taken starting from the olfactory bulbs until occipital
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TABLE 1
Mean Arterial Pressure and Arterial Blood Gas Values for Control (n = 7)
and Treated (n = 6) Animals
(MAP = mean arterial blood pressure; MAP, pO2, and pCO2 reported as
mm Hg ± standard deviation.)
MAP pO2 pCO2
(mm) (mm) (mm) pH
Control
Pre-embolization 134 ± 7 79 ± 9 40 ± 4 7.385 ± 0.08
Pre-sacrifice 131 ± 19 88 ± 17 35 ± 4 7.412 ± 0.06
p value NS NS NS NS
Treated
Pre-embolization 129 ± 9 81 ± 19 39 ± 3 7.403 ± 0.05
Pre-sacrifice 119 ± 8 88 ± 17 34 ± 4 7.428 ± 0.04
p value <.05 NS NS NS
pole tissue was no longer visible, which included the mesencephalon up to the level of
the superior colliculus but below the interpeduncular nucleus. Two initial sections were
saved from each series of 22 sections, resulting in approximately 50 saved sections per
animal. Specimens were incubated with Kodak SB-5 film for six days.
Volumetric Analysis
Of two contiguous sections saved, the more intact specimen was chosen for
photographic enlargement to 100 times original size. All autoradiographic images
were processed by the Quandens image analysis system to define areas of "no
perfusion" (of density equal to background) and "low perfusion" (20 percent of
maximal density), which were then delineated on the enlargements [7]. Thus density
and not actual blood flow was used to define regions of reduced flow. The areas of
interest in the left and right halves of the hemispheres, brain stem, and diencephalon
were measured for each image, using a microcomputer bit pad (Summagraphics Bit
Pad One), as were the total areas ofthese specimens. The results oftwo measurements
were averaged for each section. Correction for magnification in the process of
enlargement was accomplished by measurement of an enlarged 10 mm by 10 mm
standard. Volumes were then calculated, using the averages of the two analyzed
sections to represent the entire segment ofdiscarded slices which separated them.
RESULTS
One animal in each group failed to demonstrate significant regions ofhypoperfusion
(number 8 and number 15). Comparisons were made between the remaining 13
animals for purposes ofassessing drug effect.
Physiologic Measures, Anesthesia, and Fluids
Mean animal weights for the two groups were not significantly different by
one-tailed t-test (mean ± standard deviation, 413 ± 52 grams for the control group,
n = 7; 382 ± 20 g for the treated group, n = 6). Similarly, mean arterial pressures,
arterial pO2, pCO2, and pH pre-embolization and pre-sacrifice were not significantly
different (refer to Table 1). However, post-embolization pCO2 was significantly less
than pre-embolization values for both groups (p < 0.05). Mean arterial pressure fell in
both groups, reaching statistical significance only in the treated group (p < 0.05).
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TABLE 2
Raw Values for Total Brain Volume Given, Followed by Volumes Corrected for Total Brain Volume
(NF = No-Flow, LF = Low-Flow, X = mean, SD = standard deviation.)
Total Right
Brain Brain NF LF NF % of LF % of
Volume Volume Volume Volume Right Right NF/LF Fibrinogen
No. (mm3) (mm3) (mm3) (mm3) Brain Brain % mg%
Control Animals
1 1,800 912 339 564 37.2 61.8 60.1 380
2 1,655 913 214 385 23.5 42.2 55.6 280
3 1,823 889 471 651 53.0 73.2 72.4 380
4 1,813 897 417 583 46.5 65.0 71.5 260
5 1,692 886 117 263 13.2 29.6 44.4 300
6 1,628 899 283 467 31.5 51.9 60.6 375
7 1,618 895 176 328 19.7 36.6 53.8 275
X 1,718 899 288 463 32.1 51.5 59.8 321
SD 91 10 129 144 14.5 16.1 9.9 55
Treated Animals
9 1,893 945 273 420 28.9 44.4 65.1 260
10 1,591 885 172 330 19.4 37.3 52.2 200
11 1,592 896 119 237 13.3 26.5 50.2 280
12 1,662 908 225 390 24.8 43.0 57.7 350
13 1,836 909 189 358 20.8 39.3 53.0 425
14 1,520 925 328 461 35.5 49.9 71.2 300
X 1,682 911 218 366 23.8 40.1 58.2 303
SD 149 21 75 78 7.8 8.0 8.3 78
There is no clear explanation for this phenomenon. Although the drop was not great, it
should serve to increase the volume of ischemic tissue, lessening the anticipated drug
effect. Arterial blood gas values for the two animals without substantial perfusion
defects were well within the ranges measured for the other animals. The mean arterial
pressure for one of these (number 15), was higher than average (150 mm Hg
pre-embolization and 144 mm Hg pre-sacrifice).
The control animals received an average of 0.06 ± 0.01 mg/kg of pentobarbital
during theexperiment, as compared with 0.07 ± 0.02 mg/kg for thetreated group. The
difference was not statistically significant. Animals 8 and 15 (without significant
lesions), received doses which were well within the range given to the other animals.
Controls and treated animals received 0.02 ± 0.01 cc of saline per gram during the
experiment. The two animals without quantifiable lesions were given fluid doses well
within the observed range.
Observations
Treatment with PA produced no noticeable effect on the patency ofcervical vessels.
All cervical internal carotid arteries appeared to contain significant blood clot except
for those of animals 6, 7, and 12. The common carotid arteries of animals 2, 3, 9, 1 1,
and 15 also appeared darkly discolored and barely pulsatile. But for number 8, the
proximal middle and posterior cerebral arteries at the base of the brains in both
drug-treated and control animals appeared to harbor clot. Animal number 8 demon-
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FIG. 1. Rostral-caudal anatomic map ofaffected regions for animal number 11, with smallest LF (light
hatching) and NF (dark hatching) volumes. Based on atlas of Konig and Klippel, used with permission.
A, cerebral aqueduct; AC, anterior commissure; AM, amygdala; CC, corpus callosum; CP, cerebral
peduncle; D, dentate nucleus; ENT, entorhinal cortex; F, fornix; GP, globus pallidus; H, hippocampus; IC,
internal capsule; IPN, interpeduncular nucleus; LGN, lateral geniculate nucleus; MGN, medial geniculate
nucleus; NA, nucleus accumbens; NC, nucleus caudatus; OB, olfactory bulb; SC, superior colliculus; SN,
substantia nigra; TH, thalamus.
strated a small proximal middle cerebral artery (MCA) clot. Animal number 15, the
treated animal with no significant lesion, had an average amount of blood clot in
middle cerebral and internal carotid arteries by visual inspection.
Except for number 15, hyperemia ofthe cortical surface ofthe right hemisphere was
observed in all treated animals. Thecontrol animals with lower than average "no-flow"
(NF) volume (numbers 2, 5, and 7) also demonstrated hemispheric hyperemia.
No hemorrhagic lesions were identified on inspection of brain sections of either
control or drug-treated animals.
Volumetric Data
Table 2 shows thevolume values for both control and treatment groups, as corrected
for a mean total brain volume of 1,702 mm3 for the two groups. The total volumes of
hypoperfused tissue, both "no-flow" (NF) and "low-flow" (LF), was less for the
treatment group but did not reach statistical significance by the one-tailed t-test at the
0.05 level ofsignificance. There were nodifferences in the percentage oftheright brain
involved, percentage of total brain involved, the maximal NF area percentage for a
given section, or NF/LF ratios for the two groups.
Figure 1 is a reconstruction of the anatomic location of areas affected in a treated
animal (number 11) with the least NF and LF volumes based upon histological
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identification of major anatomic structures [10]. Sequential histograms of right brain
volume, NF volume, and LF volume demonstrate in standardized form the distribution
of affected tissue for all animals (Fig. 2). The greatest region of ischemia is in the
MCA distribution. As compared with the control animals, there is a significant
reduction in lesion size in the lateral cortex, internal capsule, and lenticular nuclei. The
hippocampus is nearly totally spared, as is the brain stem. There is almost no posterior
cerebral distribution involvement. As can be seen from the histogram plots, the
distribution of ischemic regions does not seem to differ substantially between the
control and treatment groups except that the drug-treated animals seemed to show a
greater amount of posterior cerebral sparing. If one considers the percentage of
involvement in the MCA distribution alone, however, one finds that the volume of LF
ischemic tissue from sections 10 through 16 inclusive (from just caudal to the caudate
head to mid-thalamus) is less for the treated animals (LF volume mean of 191 ± 45
mm3 for the control group and 150 ± 22 mm3 for the treatment group; p < 0.05). NF
differences in this region do not reach statistical significance (124 ± 52 mm3 for
control animals; 95 ± 23 mm3 for treated animals).
Further analysis of differences in average NF and LF volumes for control and
drug-treated animals based on individual volume section size from rostral to caudal
(Fig. 3) revealed a noticeable increase in average difference in sections 7 to 12
(between anterior cerebral artery and MCA primary distributions) and in sections 20
to 24 (posterior cerebral artery distribution).
LF volume for the anterior region (sections 7 to 12) was significantly less for treated
animals (47 ± 26mm3, 24.3 ± 11.9 percent of right brain) as compared with control
animals (90 ± 40.9 mm3, 42.7 ± 17.7 percent; p < 0.025). NF volumes were also
reduced but did not reach statistical significance due to a greater amount ofvariability
(23.6 ± 19.4mm3 for the treatment group vs. 49.8 ± 39.3mm3 for controls;p <0.10).
Average NF/LF ratio was 0.55 for the control group and 0.50 for the treated group in
this region.
LF and NF volumes for the posterior region (sections 20 to 24) were not
significantly different for treated animals, concomitant with a greater amount of
regional variability of involvement with this model. Average LF volume for the
treatment group was 97.1 ± 41.7 mm3, as compared with 131.4 ± 65.4 mm3 for
controls.
Finally, fibrinogen levels drawn just prior to sacrifice were not significantly different
in the control and treatment groups (Table 2).
DISCUSSION
The use of fibrinolytic agents and anticoagulants in the setting of acute cerebral
ischemia has been problematic. Attempts to use urokinase [11,12] and streptokinase
[13] in the treatment ofcerebral infarction have resulted in hemorrhagic complications
without therapeutic benefit. The use of heparin is as yet controversial [14].
Plasminogen activator, produced by vascular endothelium, promotes fibrinolysis.
PA is thought to play a role in the maintenance of vessel patency under normal
conditions. In addition, as its activity is inhibited by circulating alpha2-antiplasmin,
PA primarily works within the protective fibrin matrix of a thrombus, sparing
circulating fibrinogen, and effecting significant fibrinolysis in thrombosed vessels [15] .
Patients with non-acute cerebrovascular disease have been found to have reduced
plasminogen activator levels [16] and defective fibrinolysis [17]. A family group with
238PLASMINOGEN ACTIVATOR IN RAT STROKE MODEL
nT[rF[
Caudal Rostral
0 Right brain volume
Low flow volume
Noflow volume
FIG. 2. A. Sequential rostral-caudal
histograms for control group. Anatomic
diagram from atlas of Konig and Klippel,
used with permission. B. Sequential
rostral-caudal histograms for treated
group.
a
Caudol
-Right brain volume
-Lowflow volume
-No flow volume
E
E
E E
>
E
E
0
239PENAR AND GREER
50 ~~~~~~50
LF NF
0 ~~ ~~10 20 002
SECTION SECTION
FIG. 3. Mean difference in control and treated LF and NF volumes as percentages of mean right brain
volume per section. Calculated as mean control value minus mean treated value, expressed as percentages of
mean right brain volume in sequential rostral to caudal volume sections. Note peak in slices 7 to 12, from
nucleus accumbens to thalamus, a region of anterior-middle cerebral overlap, and in sections 20-25 in
posterior cerebral distribution.
early and frequent onset ofcerebrovascular disease associated with defective release of
vascular plasminogen activator has been identified [18].
In this study using a rat model ofcerebral ischemia, the intravenous administration
of t-PA resulted in a significant difference in the volume of "low-flow" tissue in the
control and treated animals in the middle cerebral artery vascular distribution,
apparently owing to a greater relative increase in perfusion in the anterior-middle
cerebral region ofoverlap in the treated animals. There was no consistent effect of the
drug on the apparent patency ofthecervical carotid system or on the presenceofclot in
the arteries of the circle of Willis, although this factor was not quantified; fibrinogen
levels were unaffected by drug treatment, as expected.
The small reduction in total ischemic volumes in the treated animals as compared
with controls was overshadowed by the wide range ofvalues obtained, and the relative
contribution ofmiddlecerebral artery flow tooverall brain perfusion. In this model, the
anterior cerebral distribution escapes involvement. The greatest variability occurs in
the posterior cerebral distribution. The failure to demonstrate a difference in ischemic
volumes in this same vascular distribution was probably due to this inherent variabili-
ty. In addition, NF volumes demonstrate greater variation than LF volumes, making
NF volume a less sensitive measure oftherapeutic effect.
The only observable factor which seemed to correlate with a reduction ofsize ofthe
affected region was the presence of hyperemia. All of the treated animals had a
hyperemic hemisphere, in spiteofthegenerally lowerpCO2. The threecontrol animals
with smaller than average NF and LF volumes also had hemispheric hyperemia. The
significance of hyperemia in terms of effective cerebral flow is not well established.
Post-embolic hyperemia may beassociated with a change in theposition ofthe embolus
with partial or complete reperfusion [19].
Factors which are likely to affect the results of this or other experiments with
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exogenously administered plasminogen activator include the activity ofhuman tissue-
type PA in animal species, the age ofthe occluding thrombus, and the degree ofvessel
occlusion.
The rat was chosen for this study as an inexpensive and readily available animal in
this reliable model of embolic cerebral ischemia. Small amounts of plasminogen
activator would be necessary because of the small animal size. However, rat tissue
plasminogen activator, although immunologically similar to human plasminogen
activator [20], is functionally different. In vitro studies of human tissue-type PA [21]
have shown that, as compared with 95 percent dissolution of human clots, only 10
percent dissolution occurs with rat clots in the same period of time (80 percent for
primate clots, 60 percent for cat and rabbit, and 30 percent for canine clots). A
30-minute infusion time and a dose of 12,000 IU was used in our study in order to
compare favorably with the dose and time course of drug administration used in
previous studies: human tissue PA will effectively lyse intravascular fibrin deposits in
rat lung when given in doses of300 IU or more over one hour [22]. In a rabbit model, a
1 mg/kg infusion of t-PA over 30 minutes following cerebral embolization with
autogenous clot is effective in preserving neurological function [23]. Plasminogen
activator has been shown to produce thrombolysis in canine femoral vein [3] and
coronary arteries [4,5]; clot dissolution was observed in 10 to 14 minutes with doses of
10,ug (1,000 IU)/kg/minute intravenously; however, heparin was also administered in
these studies to prevent recurrent thrombosis. Heparin was avoided in this study in
order to focus on the effects of PA infusion.
Non-cross-linked clots lyse more extensively than totally cross-linked clots. In the
rabbit model ofjugular vein thrombosis induced by foreign body, 100,000 IU of PA
infused over four hours produced 75 percent lysis of fresh clots and 35 percent lysis of
one-day-old clots [24]. As cross-linking takes approximately one hour, there is no
significant difference in the amount ofclot lysed ifthe sample is between one hour and
24 hours old [21]. Thus in our study the exact age ofthe clot should not be relevant ifit
is more than one hour old. One must bear in mind, however, that the effect of
immediate intervention in this model of stroke may poorly translate into a useful
clinical effect in humans where the opportunity to intervene within the first hour of
ischemia is infrequent. The passage of time may convert a partial occlusion to a total
occlusion, and PA may be most effective with partially occluding thrombi. Mattsson et
al. [25] showed that, in the rabbit, a two-hour infusion of 0.5 mg (approximately
50,000 IU) produced a 60 percent decrease in the weight of a partially occluding
thrombus but no significant thrombolysis in totally occluded vessels.
The relative resistance of rat blood clot to the effects of human PA is a limiting
factor which may be overcome by the use of greater doses or duration oftherapy. An
assessment ofdose-responsiveness would be of interest. Smaller volumes of clot could
be used, but this generally results in less reproducible (and bilateral) lesions. The
variability encountered with an embolic model of cerebral ischemia is a significant
factor in assessment of a treatment regimen meant to reduce the ischemic effects of
cerebral emboli.
Plasminogen activator as used in this study may improve cerebral blood flow only in
partially occluded vessels, that is to say, those on the periphery ofthe region subjected
to total vascular occlusion. Partial occlusion may occur not only because ofa relatively
small embolus, but also because of a regional low-flow state with secondary platelet
aggregation, with or without ischemic endothelial injury. As vascular plasminogen
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activator is thought to play an important role in the normal regulation of vascular
patency, one may hypothesize that exogenously administered PA may be effective in
situations ofnon-embolic cerebrovascular occlusion.
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